US2259698A
(en)
|
1938-05-07 |
1941-10-21 |
Rare Chemicals Inc |
Physiologically effective substance and process of preparing same
|
US2594323A
(en)
|
1948-07-22 |
1952-04-29 |
Upjohn Co |
24-substituted delta 5-cholene-3, 24-diols
|
US3079385A
(en)
|
1961-01-24 |
1963-02-26 |
Roussel Uclaf |
Novel process of preparation of polyhydroxylated pregnanes
|
US3206459A
(en)
|
1962-10-19 |
1965-09-14 |
Syntex Corp |
10alpha-pregnan-19-ol derivatives
|
JPS5324071B2
(fr)
|
1974-04-30 |
1978-07-18 |
|
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
CH628907A5
(en)
|
1975-10-10 |
1982-03-31 |
Hoffmann La Roche |
Process for the preparation of 24,25-dihydroxycholesterol derivatives
|
JPS5840960B2
(ja)
|
1976-12-28 |
1983-09-08 |
帝人株式会社 |
ヒドロキシコレステロ−ル立体異性体間の相互変換法
|
JPS54163565A
(en)
|
1978-06-09 |
1979-12-26 |
Teijin Ltd |
24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
|
JPS5735597A
(en)
|
1980-08-13 |
1982-02-26 |
Teijin Ltd |
25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
|
JPS61254599A
(ja)
|
1985-05-07 |
1986-11-12 |
Sumitomo Pharmaceut Co Ltd |
コレステロ−ルのフツ素誘導体
|
JPS62187485A
(ja)
|
1986-02-13 |
1987-08-15 |
Teijin Ltd |
24,25−エポキシコレステロ−ル類の製造法
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
AU698834B2
(en)
|
1993-05-24 |
1998-11-12 |
Purdue Pharma Ltd. |
Methods and compositions for inducing sleep
|
IL110309A0
(en)
|
1993-07-15 |
1994-10-21 |
Univ Kentucky Res Found |
A method of protecting against neuron loss
|
DE4338316A1
(de)
|
1993-11-10 |
1995-05-11 |
Jenapharm Gmbh |
Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
|
ATE195654T1
(de)
|
1994-02-14 |
2000-09-15 |
Euro Celtique Sa |
Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
|
TW385308B
(en)
|
1994-03-04 |
2000-03-21 |
Merck & Co Inc |
Prodrugs of morpholine tachykinin receptor antagonists
|
US5595996A
(en)
|
1994-10-25 |
1997-01-21 |
Merck & Co., Inc. |
7-substituted 4-aza cholanic acid derivatives and their use
|
ATE198753T1
(de)
|
1994-11-23 |
2001-02-15 |
Cocensys Inc |
Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
|
JPH08268917A
(ja)
|
1995-03-31 |
1996-10-15 |
D D S Kenkyusho:Kk |
癌組織への移行性の高い制癌剤
|
BR9608592A
(pt)
|
1995-06-06 |
1999-06-29 |
Cocensys Inc |
Esteróides neuroativos da série do androstano e do pregnano
|
US5792635A
(en)
|
1995-06-07 |
1998-08-11 |
Magainin Pharmaceuticals, Inc. |
Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
|
AU718246B2
(en)
|
1995-06-23 |
2000-04-13 |
Novo Nordisk A/S |
Meiosis regulating compounds
|
US6645953B2
(en)
|
1995-06-23 |
2003-11-11 |
Novo Nordisk A/S |
Meiosis regulating compounds
|
US5888996A
(en)
|
1995-07-26 |
1999-03-30 |
Trustees Of Boston University |
Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
|
WO1997003677A1
(fr)
|
1995-07-24 |
1997-02-06 |
Trustees Of Boston University |
Inhibition de l'activite des recepteurs du n-methyl-d-aspartate au moyen de derives de sulfate de pregnenolone
|
JPH09328498A
(ja)
|
1996-06-10 |
1997-12-22 |
Teijin Ltd |
24,25−ジヒドロキシコレステロールの製造法およびその合成中間体
|
AU3967297A
(en)
|
1996-08-01 |
1998-02-25 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
DE19635525A1
(de)
|
1996-08-20 |
1998-02-26 |
Schering Ag |
7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
US7012069B2
(en)
|
2001-05-03 |
2006-03-14 |
Arch Development Corporation |
Liver X receptor agonists
|
WO1999058497A1
(fr)
|
1998-05-11 |
1999-11-18 |
Novo Nordisk A/S |
Guanidines et diaminonitroethenes substituees, preparation et applications
|
IL139241A0
(en)
|
1998-05-13 |
2001-11-25 |
Novo Nordisk As |
Meiosis regulating compounds
|
US8541600B2
(en)
|
1998-11-24 |
2013-09-24 |
Harbor Therapeutics, Inc. |
11-aza, 11-thia and 11-oxa sterol compounds and compositions
|
DE19917930A1
(de)
|
1999-04-15 |
2000-10-19 |
Schering Ag |
Ent-Steroide als selektiv wirksame Estrogene
|
US6376530B1
(en)
|
1999-05-10 |
2002-04-23 |
Merck & Co., Inc. |
Cyclic amidines useful as NMDA NR2B antagonists
|
GB9910934D0
(en)
|
1999-05-11 |
1999-07-14 |
Res Inst Medicine Chem |
Chemical compounds
|
CN1098273C
(zh)
|
1999-11-12 |
2003-01-08 |
中国科学院上海有机化学研究所 |
高立体选择性的合成24r,25-和24s,25-二羟基甾体化合物
|
GB0000228D0
(en)
|
2000-01-06 |
2000-03-01 |
Phytopharm Plc |
Fluoro substituted sapogenins and their use
|
GB0019290D0
(en)
|
2000-08-04 |
2000-09-27 |
Symphar Sa |
Methods for inducing apolipoprotein E secretion
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
GB0107822D0
(en)
|
2001-03-28 |
2001-05-23 |
Phytopharm Plc |
Sapogenin derivatives their synthesis and use methods based upon their use
|
US20070197484A1
(en)
|
2001-05-03 |
2007-08-23 |
Ching Song |
Method of treating disorder related to high cholesterol concentration
|
CA2466033A1
(fr)
|
2001-11-08 |
2003-05-15 |
The University Of Chicago |
Methode de traitement de troubles lies a un taux de cholesterol eleve
|
AU2002360489A1
(en)
|
2001-12-07 |
2003-06-23 |
The Regents Of The University Of California |
Treatment for age-related macular degeneration
|
CN102727501A
(zh)
|
2002-03-27 |
2012-10-17 |
菲特法姆股份有限公司 |
皂角苷配基及其衍生物的用途
|
RU2332999C2
(ru)
|
2002-03-27 |
2008-09-10 |
ФИТОФАРМ ПиЭлСи |
Терапевтические способы и применения сапогенинов и их производных
|
GB0216621D0
(en)
|
2002-07-17 |
2002-08-28 |
Imaging Res Solutions Ltd |
Imaging compounds
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
JP2006509763A
(ja)
|
2002-11-22 |
2006-03-23 |
メルク エンド カムパニー インコーポレーテッド |
Nr2b受容体アンタゴニストとしての2−[(4−ベンジル)−1−ピペリジニル)メチル]ベンゾイミダゾール−5−オール誘導体
|
AU2003288231A1
(en)
|
2002-12-13 |
2004-07-09 |
Bayer Healthcare Ag |
Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
|
FR2850023B1
(fr)
|
2003-01-17 |
2007-04-06 |
Mapreg |
Medicaments pour le systeme nerveux
|
GB0403889D0
(en)
|
2004-02-21 |
2004-03-24 |
Univ Edinburgh |
Uses of er-beta modulators
|
US8604011B2
(en)
*
|
2004-09-27 |
2013-12-10 |
The Regents Of The University Of California |
Therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
US20070032464A1
(en)
|
2004-10-08 |
2007-02-08 |
Shutsung Liao |
Methods of treating cancers
|
JP2008518935A
(ja)
|
2004-11-01 |
2008-06-05 |
セオ ホン ユー |
筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
|
US9670244B2
(en)
|
2006-02-27 |
2017-06-06 |
The Regents Of The University Of California |
Oxysterol compounds and the hedgehog pathway
|
CN101164540A
(zh)
|
2006-08-03 |
2008-04-23 |
中山大学 |
海洋甾体化合物在制备治疗神经元损伤药物中的应用
|
GB0619860D0
(en)
|
2006-10-06 |
2006-11-15 |
Birkeland Innovasjon As |
Treatment of insulin resistance and disorders associated therewith
|
WO2008057468A1
(fr)
|
2006-11-02 |
2008-05-15 |
Curis, Inc. |
Régulateurs à petites molécules organiques de la prolifération cellulaires
|
EP2097437B1
(fr)
|
2006-11-21 |
2015-05-27 |
Umecrine Cognition AB |
Utilisation de stéroïdes dérivés du prégnane et de l'androstane pour la fabrication d'une composition pharmaceutique pour le traitement de troubles du snc
|
KR101583737B1
(ko)
|
2007-06-20 |
2016-01-11 |
오스펙스 파마슈티칼스, 인코포레이티드 |
섬유증 저해제로서의 치환된 n-아릴 피리디논
|
GB0712494D0
(en)
|
2007-06-27 |
2007-08-08 |
Isis Innovation |
Substrate reduction therapy
|
US20110118353A1
(en)
|
2007-11-06 |
2011-05-19 |
N. V. Organon |
Method of hormone suppression in humans
|
EP2231164A1
(fr)
|
2007-12-03 |
2010-09-29 |
The Regents of the University of California |
Oxystérols pour l'activation du signal hedgehog, de l'ostéoinduction, de l'anti-adipogenèse et du signal wnt
|
WO2009090063A1
(fr)
|
2008-01-16 |
2009-07-23 |
Jado Technologies Gmbh |
Dérivés de sapogénine stéroïde, androstane et sapogénine triterpénoïde pour le traitement et la prévention de maladies infectieuses
|
WO2009094279A1
(fr)
|
2008-01-25 |
2009-07-30 |
Merck & Co., Inc. |
Modulateurs allostériques positifs du récepteur m1 de type quinolizidinone
|
CA2722776A1
(fr)
|
2008-05-09 |
2009-11-12 |
Emory University |
Antagonistes des recepteurs nmda utilisables pour le traitement de troubles neuropsychiatriques
|
WO2010065709A2
(fr)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Dérivés d'acide hydroxamique, préparation et utilisations thérapeutiques de ceux-ci
|
WO2010075282A1
(fr)
|
2008-12-22 |
2010-07-01 |
University Of Washington |
Inhibiteurs moléculaires de la voie wnt/bêta-caténine
|
US20110319416A1
(en)
|
2009-01-28 |
2011-12-29 |
Emory University |
Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
|
EP2459581A4
(fr)
|
2009-07-29 |
2012-12-26 |
Univ Chicago |
Agonistes du récepteur x du foie
|
WO2011028794A2
(fr)
|
2009-09-01 |
2011-03-10 |
Lazarus Therapeutics, Inc. |
Traitement de la chorée de huntington avec de la cyclosérine et un agoniste des récepteurs nmda
|
FR2953138B1
(fr)
|
2009-12-02 |
2015-10-16 |
Assist Publ Hopitaux Marseille |
Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
|
WO2011092127A1
(fr)
|
2010-01-26 |
2011-08-04 |
Bayer Schering Pharma Aktiengesellschaft |
Dérivés d'estratriène 14,17-pontés comprenant des bioisostères hétérocycliques pour le noyau phénolique a
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
GB201008047D0
(en)
|
2010-05-14 |
2010-06-30 |
Ge Healthcare Ltd |
Method of synthesis
|
US20120035156A1
(en)
|
2010-08-09 |
2012-02-09 |
Daniela Alberati |
Combination of glyt1 compound with antipsychotics
|
US8969525B2
(en)
|
2010-11-09 |
2015-03-03 |
Enzo Life Sciences, Inc. |
Hydroxycholesterol immunoassay
|
US20150031655A1
(en)
|
2011-04-15 |
2015-01-29 |
University Of North Dakota |
Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
|
EP2714081A4
(fr)
|
2011-05-27 |
2015-09-09 |
Cytocure Llc |
Méthodes, compositions et trousses pour le traitement du cancer
|
CA2843436A1
(fr)
|
2011-07-29 |
2013-02-07 |
The Regents Of The University Of California |
Nouveaux steroides substitues en 17? par un heteroaryle, capables de moduler les recepteurs gabaa
|
US20150158903A1
(en)
|
2011-09-08 |
2015-06-11 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
ES2716531T3
(es)
|
2011-10-07 |
2019-06-13 |
Takeda Pharmaceuticals Co |
Compuestos de 1-arilcarbonil-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
|
CA2852057C
(fr)
*
|
2011-10-14 |
2022-06-07 |
Sage Therapeutics, Inc. |
Composes 19-nor-pregnane 3,3-disubstituees, compositions et utilisationsassociees dans le traitement de troubles associes au snc
|
EP2841067A4
(fr)
|
2012-04-25 |
2016-04-13 |
Univ California |
Plate-forme de criblage de médicaments pour le syndrome de rett
|
WO2014025942A1
(fr)
|
2012-08-09 |
2014-02-13 |
Emory University |
Modulateurs de récepteur nmda et utilisations associées à ceux-ci
|
BR112015014397B1
(pt)
|
2012-12-18 |
2021-02-02 |
Washington University |
composto, composição farmacêutica e uso de um composto
|
CN112552364A
(zh)
|
2013-01-23 |
2021-03-26 |
司菲埃拉制药私人有限公司 |
用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物
|
CA2898863A1
(fr)
|
2013-01-29 |
2014-08-07 |
Naurex, Inc. |
Modulateurs spirolactames d'un recepteur nmda et leurs utilisations
|
AU2014243819A1
(en)
|
2013-03-13 |
2015-10-01 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
PT3461834T
(pt)
|
2013-03-13 |
2021-09-10 |
Sage Therapeutics Inc |
Esteroides neuroativos
|
KR20160060688A
(ko)
|
2013-09-25 |
2016-05-30 |
반 안델 리서치 인스티튜트 |
고도로 강력한 글루코코르티코이드
|
JP6628745B2
(ja)
*
|
2014-06-18 |
2020-01-15 |
セージ セラピューティクス, インコーポレイテッド |
オキシステロールおよびその使用方法
|
US10238664B2
(en)
|
2014-07-09 |
2019-03-26 |
Duke University |
Compositions and methods for the repair of myelin
|
US20170304321A1
(en)
|
2014-10-07 |
2017-10-26 |
Sage Therapeutics, Inc. |
Neuroactive compounds and methods of use thereof
|
CN108135911B
(zh)
|
2015-07-06 |
2021-06-25 |
萨奇治疗股份有限公司 |
氧甾醇及其使用方法
|
SG10202010553XA
(en)
|
2015-07-06 |
2020-12-30 |
Sage Therapeutics Inc |
Oxysterols and methods of use thereof
|
JP6882996B2
(ja)
|
2015-07-06 |
2021-06-02 |
セージ セラピューティクス, インコーポレイテッド |
オキシステロールおよびそれらの使用の方法
|
GB2557875A
(en)
|
2015-09-02 |
2018-07-04 |
Univ Swansea |
Diagnostic methods and kits
|
ES2921010T3
(es)
|
2016-04-01 |
2022-08-16 |
Sage Therapeutics Inc |
Oxisteroles y procedimientos de uso de los mismos
|
WO2017193046A1
(fr)
|
2016-05-06 |
2017-11-09 |
Sage Therapeutics, Inc. |
Oxystérols et méthodes d'utilisation associées
|
PL3481846T3
(pl)
|
2016-07-07 |
2021-12-20 |
Sage Therapeutics, Inc. |
11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
|
US20190233465A1
(en)
|
2016-07-11 |
2019-08-01 |
Sage Therapeutics, Inc. |
C7, c12, and c16 substituted neuroactive steroids and their methods of use
|
US11149056B2
(en)
|
2016-09-30 |
2021-10-19 |
Sage Therapeutics, Inc. |
C7 substituted oxysterols and methods of use thereof
|
JP2019532079A
(ja)
|
2016-10-18 |
2019-11-07 |
セージ セラピューティクス, インコーポレイテッド |
オキシステロールおよびその使用方法
|
US11149054B2
(en)
*
|
2016-10-18 |
2021-10-19 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
EP3595727A1
(fr)
|
2017-03-15 |
2020-01-22 |
ModernaTX, Inc. |
Formulation de nanoparticules lipidiques
|
WO2018237350A1
(fr)
|
2017-06-23 |
2018-12-27 |
Intercept Pharmaceuticals, Inc. |
Procédés et intermédiaires pour la préparation de dérivés de l'acide biliaire
|
SG11202004329TA
(en)
|
2017-11-10 |
2020-06-29 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in treating genetic epileptic disoders
|
TW202110824A
(zh)
|
2019-05-24 |
2021-03-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|